daytrade diaries... july 20, page-15

Do not know how many times i have called STI, not a day trade but take a look at latest annoucement

Breakthrough Study Results Show High Cure Rate in TB and
AIDS Co-infected Patients.
FOR IMMEDIATE RELEASE
20 July 2009
Australian healthcare company Stirling Products Administration (ASX:STI) advises the
publication of breakthrough study results showing a high rate cure of TB patients co-infected
with HIV who received its immunomodulator Immunoxel (Dzherelo). The study appeared in this
month’s issue of Immunotherapy - published by Future Medicine – a division of London UK
based Future Science Group. (http://www.futuremedicine.com/loi/imt)
Adjunct immunotherapy with herbal supplement Immunoxel (Dzherelo) combined with first-line
TB drugs resulted in clearance of Mycobacterium tuberculosis in sputum cultures: 67% vs. 16%
patients treated with TB drugs alone, with average time to negative culture 4 and 6 months
respectively. Immunoxel, given at 50 drops twice-per-day dose, resulted in higher healing rate
of cavitary/ miliary involvements - i.e. 60%/84% in Immunoxel patients and 25%/46% in ATT
alone patients. Immunotherapeutic intervention produced significant positive changes in body
weight: 5.8±2.6 kg gain vs. 0.6±2.4 kg loss in ATT only patients. The Incidence of opportunistic
infections reduced in ATT + Immunoxel patients - 3 episodes vs. 12 episodes in ATT alone
patients.
In the clinical study, antiretroviral drug-naïve, TB/HIV co-infected patients with active pulmonary
TB, were divided into two arms A (n=20) and B (n=20) to receive first-line anti-TB therapy (ATT)
alone or ATT + Immunoxel respectively. In the study, 3 (16%) versus 12 (67%) (p=0.003)
patients had Mycobacterium tuberculosis culture conversion, with time to negative culture 6 and
4 months in arms A and B respectively. In the ATT alone arm the healing of pulmonary
cavitations was observed in 25% of patients at weeks 24-28, while 60% of individuals in arm B
healed at 16-18 weeks (p=0.025). The TB lesions, on chest X-ray, had cleared in 46% in the
ATT arm and 84% in the Immunoxel arm, with time to clearance 24-28 and 16-18 weeks
respectively. In the ATT alone arm the body weight at baseline was 64±6.3 kg, with 13 cachexic
patients who had an average weight deficit -5.2±1.7 kg. At the end of 6 months of follow-up
they have lost an additional 0.6 kg (-5.8±2.4). The study entry level weight in arm B was 52±5.7
kg, with 12 individuals who had body mass deficit -8.5±2.7 kg. The Immunoxel intervention
increased body weight by an average 5.8±2.6 kg above baseline (p<0.0001). The inclusion of
Immunoxel into the ATT regimen decreased the incidence of new opportunistic infections with 3
episodes of infection versus 12 in arm A (p=0.003). These findings demonstrate that
Immunoxel can contribute positively to the clinical efficacy of tuberculosis treatement drugs